We need your help in advocating to our provincial and territorial governments to ensure that all Health Canada-approved PAH medications are accessible to patients—at diagnosis and beyond. Patients’ lives depend on ensuring that initial access to PAH medications is not limited.
The challenge the PAH community currently faces is that the recently released Therapeutic Review Recommendation Report for Drugs for PAH seeks to severely restrict physicians’ ability at diagnosis to exercise the individual clinical judgement essential to the proper treatment of PAH. It is important that the provinces and territories do not implement these recommendations, and that all Health Canada-approved PAH medications are accessible to PAH patients as initial therapy. A one-size-fits-all approach to managing this rare disease will not work, and lives could be at risk. With your support, we can make a difference for all of those affected by PAH. The voice of every person affected by Pulmonary Hypertension is crucial.
See how you can contribute: http://www.phacanada.ca/en/get-involved/advocacy/
Read the full CADTH Recommendations Report here: https://www.cadth.ca/drugs-pulmonary-arterial-hypertension
Join and share our Facebook Event: https://www.facebook.com/events/1457754531197750/
Visit http://www.takeactionpah.ca/ for more information.